Potential of Aqueous Humor as a Liquid Biopsy for Uveal Melanoma.
aqueous humor
circulating-tumor DNA
liquid biopsy
uveal melanoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Jun 2022
02 Jun 2022
Historique:
received:
07
05
2022
revised:
27
05
2022
accepted:
30
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Tumor biopsy can identify prognostic biomarkers for metastatic uveal melanoma (UM), however aqueous humor (AH) liquid biopsy may serve as an adjunct. This study investigated whether the AH of UM eyes has sufficient circulating tumor DNA (ctDNA) to perform genetic analysis. This is a case series of 37 AH samples, taken before or after radiation, and one tumor wash sample, from 12 choroidal and 8 ciliary body (CB) melanoma eyes. AH was analyzed for nucleic acid concentrations. AH DNA and one tumor wash sample underwent shallow whole-genome sequencing followed by Illumina sequencing to detect somatic copy number alterations (SCNAs). Four post-radiation AH underwent targeted sequencing of
Identifiants
pubmed: 35682905
pii: ijms23116226
doi: 10.3390/ijms23116226
pmc: PMC9181140
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : K08 CA232344
Pays : United States
Organisme : Knights Templar Eye Foundation
ID : na
Organisme : Research to Prevent Blindness
ID : na
Organisme : NCI NIH HHS
ID : K08CA232344
Pays : United States
Organisme : Berle & Lucy Adams Chair in Cancer Research
ID : na
Références
Ocul Oncol Pathol. 2021 Mar;7(1):1-16
pubmed: 33796511
Br J Ophthalmol. 2019 Feb 11;:
pubmed: 30745306
Mol Cancer Res. 2018 Nov;16(11):1701-1712
pubmed: 30061186
Medicine (Baltimore). 2019 Feb;98(5):e14030
pubmed: 30702560
Cancers (Basel). 2019 Aug 18;11(8):
pubmed: 31426578
Am J Ophthalmol. 2016 Feb;162:28-34.e1
pubmed: 26556006
Cancers (Basel). 2021 Mar 13;13(6):
pubmed: 33805776
Ophthalmology. 2012 Aug;119(8):1596-603
pubmed: 22521086
Medicine (Baltimore). 2020 Sep 18;99(38):e22091
pubmed: 32957329
Ophthalmology. 2018 Dec;125(12):1969-1976
pubmed: 29705056
JAMA Ophthalmol. 2016 Jul 1;134(7):728-33
pubmed: 27123562
Cancers (Basel). 2019 Jun 20;11(6):
pubmed: 31226786
Invest Ophthalmol Vis Sci. 2014 Jun 26;55(8):5160-7
pubmed: 24970262
Adv Radiat Oncol. 2021 Jun 11;6(5):100737
pubmed: 34307966
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4740-4747
pubmed: 31731294
Ophthalmology. 2022 Apr;129(4):421-430
pubmed: 34780841
Ophthalmology. 2018 Aug;125(8):1139-1142
pubmed: 30032793
JAMA Ophthalmol. 2017 Nov 1;135(11):1221-1230
pubmed: 29049475
Ophthalmology. 2022 Apr;129(4):431-437
pubmed: 34793831
Br J Cancer. 2017 Sep 5;117(6):884-887
pubmed: 28809862
Annu Rev Pathol. 2009;4:199-227
pubmed: 18817506
J Mol Diagn. 2021 Dec;23(12):1714-1721
pubmed: 34656762
Nat Protoc. 2012 May 03;7(6):1024-41
pubmed: 22555242
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Ophthalmology. 2017 May;124(5):609-618
pubmed: 28159380
Acta Ophthalmol. 2018 Feb;96(1):31-38
pubmed: 28444874
J Vis Exp. 2021 Sep 7;(175):
pubmed: 34570090
Acta Ophthalmol. 2011 Feb;89(1):17-24
pubmed: 21272286
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Mol Cancer Res. 2020 Aug;18(8):1166-1175
pubmed: 32434859
Ophthalmology. 2012 Aug;119(8):1582-9
pubmed: 22503229
BMC Res Notes. 2015 Sep 17;8:452
pubmed: 26383622
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):833-842
pubmed: 28159971
Nat Commun. 2020 May 15;11(1):2408
pubmed: 32415113
Invest Ophthalmol Vis Sci. 2014 Dec 23;56(1):438-44
pubmed: 25537201
Acta Ophthalmol. 2012 Jun;90(4):e314-20
pubmed: 22429778